Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of acute STEMI（meet with both conditions）:~   * Ischemic chest pain ≥30mins in duration~  * ST elevation ≥0.1 mV in two or more limb ECG leads or ≥0.2 mV in two or more contiguous precordial leads~2. Onset of continuous ischemic symptoms of STEMI ≤6 hours prior to randomisation~3. Anticipated Delay to Performing Primary PCI \>60mins，or time from hospital arrival to to balloon inflation \>90mins~4. Signed Informed consent received prior to participation the study~Exclusion Criteria:~1. Non-ST-segment-elevation myocardial infarction or unstable angina~2. Reinfacrtion~3. Cardiacgenic shock~4. Suspected aortic dissection~5. New left bundle branch block in ECG~6. Absolute and relative contraindications for Fibrinolytic Therapy in STEMI(referred from 2015 China STEMI Management Guideline）：~   * Severe uncontrolled hypertension (unresponsive to emergency Therapy,BPs \> 180 mmHg and/or BPd \> 110 mmHg)~  * Any prior ICH,stroke with unknown cause, Ischemic stroke within 3 months~  * Known structural cerebral vascular lesion, malignant intracranial neoplasm~  * Active bleeding, or bleeding diathesis, active peptic ulcer~  * Significant closed-head or facial trauma within 3 months~  * Intracranial or intraspinal surgery within 2 months~  * Recent internal bleeding within 4 weeks~  * Major surgery within 3 weeks, or Traumatic~  * Prolonged cardiopulmonary resuscitation (\>10 minutes)~  * Noncompressible vascular punctures within 2 weeks~  * Current use of anticoagulant therapy~7. Current or with a history of significant diseases：~   * Damage to the central nervous system~  * Severe renal or hepatic dysfunction, blood system diseases,~  * Present with cardiac rupture evidence~  * Acute pericarditis,Subacute bacterial endocarditis, Septic thrombophlebitis or occluded AV cannula at seriously infected site~  * Malignancy~  * High likelihood of left heart thrombus, e.g., mitral stenosis with atrial fibrillation~  * Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions~  * History of PCI or coronary artery bypass graft（CABG）within 1 month~8. Administration of fibrinlytic therapy prior to participation~9. Weight below 50 kg~10. Known current histroy of fall-down accident~11. Any other unfavourable conditions for participation：~    * Known participation in other clinical trials~   * Known to allergic to rhTNK-tPA or tPA or relevant vehicle~   * Pregnancy or lactation~   * Mental disorder~   * Present with any unsuitable conditions for participation or completion of the study at the discretion of their treating physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- rhTNK-tPA (Type: EXPERIMENTAL): rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
- rt-PA (Type: ACTIVE_COMPARATOR): Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).